INTRODUCTION
The life expectancy of individuals with cystic fibrosis (CF) has dramatically improved in the past 75 years [1 && ]. In 1938, the life expectancy was less than 1 year, and only improved to 16 years by the mid-1970s [2] . CF continues to be the leading singlegene life-limiting disorder in whites, affecting one in 3500 children born in the USA [1 && ]. Currently, there are approximately 30 000 individuals with CF in the USA. Manifestations of the disorder are primarily related to the defective chloride channel functioning of the CF transmembrane conductance regulator (CFTR); however, other associated problems are believed to be the result of the cellular responses to the mutant CFTR protein or its production. The most recognized of these problems result from the mucous blockage and obstruction of the lungs, as well as the early fibrotic destruction of the pancreas. Remarkably, through improvements in therapy, the predicted life expectancy of individuals is now 36.8 years, as reported by the Cystic Fibrosis Foundation [1 && ].
However, this increase in the life expectancy has come with costs, as new complications have emerged. Endocrine disorders, primarily CF-related diabetes (CFRD) and CF-related bone disease (CFBD), are the leading complications associated with CF [1 && ]. The CF Patient Registry reports that 19% of all individuals with CF have CFRD, occurring in 32.6% of individuals 18 years and older. Registry data also indicate that CFBD currently affects 11% of individuals with CF, although other authors report higher numbers. This finding may represent The association of low bone density in CF was first described in 1979. Mischler et al. [3] found that 44% of the CF patients had a bone mineral content (BMC) more than 2 SD below controls. Interestingly, they reported this finding to be more prevalent in women. Furthermore, they noted that these findings were confounded by short stature, delayed bone age and low body weight. This study not only documented the first report of CFBD but also illustrated some of the problems and systemic influences complicating bone health, with special emphasis on lung health and nutrition.
Since that time, multiple studies have documented the incidence of bone disease in this population. One such study in late-stage adult CF patients, referred for lung transplant, reported that 57% of patients had osteoporosis [4] . This further translated to a 100-fold greater risk of vertebral compression fracture. In this population, compression fractures can further impair lung function and may disqualify a patient for transplantation. However, the true impact on fracture risk is debatable, especially in children. Rovner et al. [5] evaluated the lifetime fracture history in 186 CF children and young adults with pancreatic insufficiency and mild to moderate lung disease. The authors found no increased fracture risk compared with healthy controls. Nevertheless, a study by Latzin et al. [6] exemplified the worrisome nature of the problem, in an extreme case of pathologic fracture resulting in the fatality of a 16-year-old girl. They describe her spontaneous sternal fracture resulting in severe respiratory distress.
Briefly stated, CFBD is an example of a multifactorial disorder, contributed by vitamin D deficiency, nutrition, hypogonadism, increased inflammatory cytokines and glucocorticoid therapies. In addition, male sex, advanced lung disease, malnutrition and low fat-free body mass are established additional risk factors for CFBD [7] [8] [9] . Furthermore, emerging data suggest a direct genetic component to the development of low bone density. The F508del-CFTR mutation is the most common mutation resulting in CF in the USA, with almost 87% of CF individuals having at least one copy and 47% homozygous for this mutation [1 && ]. F508del-CFTR in itself, compared with other mutations, is associated with a reduced bone density in adults with CF [9] . These contributors and risk factors will be further discussed in this review.
SCREENING RECOMMENDATIONS
The CF Foundation currently recommends that all individuals with CF should undergo a DXA scan assessment at the age of 18 years [1 && ,7,10]. Patients with normal BMD should undergo repeat DXA testing every 5 years. If the DXA Z-score is less than -1 but more than -2, the study should be repeated every 2-4 years. Lastly, if the Z-score is less than or equal to -2, treatment should be considered and DXA assessment repeated yearly. Previously, the consensus on bone health in CF also recommended DXA screening of children greater than 8 years with significant risk factors for bone disease [7] .
The current recommendations utilize DXA scanning for the assessment of bone density [7] . However, strategies to improve screening compliance, cost and exposure to radiation are a subject of current study. De Schepper et al. ] recently compared the use of quantitative ultrasound bone sonometry (QUS) in 64 adolescents (aged >12 years) and young adults (aged <40 years) with CF, with the traditional DXA scan as well as peripheral quantitative computed tomography (pQCT) of the radius. They reported that QUS had a sensitivity of zero per cent and specificity of 96% for diagnosing osteopenia, based on whole body BMC Z-score less than -2. Furthermore, they stated a positive and negative predictive value of zero and 90%, respectively. The authors did conclude that the QUS may be utilized to identify patients with normal bone mass. Additional studies are needed to refine screening strategies, as well as to assess those individuals at greatest risk for fracture. These findings will aid in the identification of the group of patients that would most benefit from treatment.
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CFBD is a multifactorial disorder, stemming from both direct and indirect contributors from the underlying cystic fibrosis defect.
All individuals with cystic fibrosis should be screened for CFBD, as well as screened for known contributors to the disease (such as vitamin D deficiency).
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As previously mentioned, CFBD is a classic example of a multifactorial disorder. Although some of these factors have established associations with CF, the remaining contributors are based on data from other disease states (Fig. 1 ). The summation of these influences result in a bone metabolic state of uncoupled turnover. In other words, decreased osteoblast bone formation coupled with increased osteoclastic bone resorption is characteristic of CFBD (Fig. 2) .
Probably the most recognized, vitamin D deficiency with resultant reduced calcium gut absorption continues to be complicating factors in CF bone health. Given the difficulties of absorption of vitamin D in CF patients, low concentrations of 25-hydroxy vitamin D are frequent. Somewhat refuting this concern, a study by Haworth et al. [12] examined vertebral biopsy histomorphometric parameters of CF individuals. They found severe osteopenia, but not changes consistent with vitamin D dependent osteomalcia. Interestingly, histomorphometric examination revealed decreased osteoblast with increased osteoclast activity, a characteristic of CFBD.
Deficiencies in vitamin D and calcium increase bone turnover through the stimulation of parathyroid hormone (PTH) production. Increased levels of PTH have been reported as a response to reduced total body calcium [13, 14] . The increase in PTH stimulates osteoclastogenesis and subsequent bone reabsorption, to restore normal circulating calcium concentration. Corticosteroid therapy is another probable culprit in CFBD, especially in the post-transplant individuals. With corticosteroids, there is a reduction in calcium absorption from the gut, and an increase in urinary calcium excretion. In addition, corticosteroids increase osteoclastogenesis through the production of receptor activator of nuclear factor-kappa B ligand (RANKL) [15] .
CF related bone disease
CFBD development may be largely related to the role of the chronic inflammatory state. In CF, there is evidence of upregulation of the nuclear factorkappa B (NF-kB) pathway [16] that correlates with BMC, and interleukin (IL)-6 and C-reactive protein concentrations [9, 17, 18] . Furthermore, Shead et al. [19] reported increased osteoclast precursors during CF pulmonary exacerbations.
New insights into CFRD suggest that there is a chronic insulin-deficient state [20] . As an influence on bone metabolism, insulin stimulates osteoblast proliferation and function, as well as endochondral bone growth. Diabetes, whether through an insulindeficient state or hyperglycemia, is well recognized as a risk factor for the development of osteoporosis in non-CF individuals [21] [22] [23] . In a recent study by Rana et al. [24 & ], the authors compared DXA scan results and diabetes status (based on oral glucose tolerance testing) in 81 CF patients 18 years or less of age. They describe an association of dysglycemia and reduced bone density in the CF population.
Other pro-anabolic factors such as insulin-like growth factor I (IGF-I) and sex hormones must not be overlooked. Decreased IGF-I concentrations are described in individuals with CF, despite normal stimulated growth hormone responses [25] . This finding is also noted in animal models of CF [26] . Furthermore, IGF-I correlates with bone density in CF patients [27] . Regarding the sex hormones, hypogonadism is well associated with decreased bone density. Although this contribution to CFBD has not been formally entrenched, both men and women with CF have a significant risk of hypogonadism [28, 29] . This finding has however been associated with an increase in vertebral fractures in CF [30] .
Data surrounding the genetic contribution of CF in the development of CFBD are mounting. Animal studies of CFTR-deficient mice imply a direct effect on bone metabolism. Multiple studies [31] [32] [33] [34] involving the CF mouse, both the Cftr knockout (Cftr-/-) and the F508del-CFTR models, demonstrate reduced bone density. The use of mouse models eliminates other clinical variables, namely lung disease and chronic malnutrition that are absent in these models [33, 35, 36] . Reinforcing these findings, a validation to the idea of a genetic contribution came in a 2007 article by Shead et al. [37] , in which the authors report detection of CFTR on human osteoblasts and osteoclasts.
To detail this genetic component of CFBD, we turn to data by our own laboratory. We recently reported the expression of Cftr mRNA, as well as immunohistochemistry staining of CFTR, in murine osteoblasts [38 & ]. However, we neither detected expression of Cftr mRNA nor immunohistochemical staining in the murine osteoclast. This conflicts with the above study by Shead et al. [37] and may reflect differences in antibody specificity and/or expression differences in human versus murine osteoclasts. From these findings, we suspected an intracellular signalling component that drives the increased bone resorption that is characteristic of CFBD.
Building off the above data, we demonstrated reduced bone formation and fewer osteoblasts in Cftr-/-murine calvarial organ cultures compared with wildtype controls [38 & ]. Osteoblast primary cell cultures also exhibited less alkaline phosphatase staining in Cftr-/-cultures indicating a differentiation defect. Osteoclasts were then grown from Cftr-/-bone marrow cultures and were found to be in greater numbers than wildtype cultures, despite the lack of osteoclast CFTR expression. A mechanistic study of this discovery revealed a decrease in osteoprotegerin (OPG) expression in Cftr-/-osteoblasts, but no differences in expression of the receptor activator of NF-kB ligand (Rankl). This results in an increase in the Rankl to OPG ratio that drives osteoclastogenesis. From these results, we concluded that CFTR deficiency impairs osteoblast differentiation and bone production, as well as indirectly increasing osteoclastic bone resorption. ] recently published an update on guidelines for the screening and treatment of vitamin D deficiency in CF. They detailed the CF Foundation nutritional guidelines, suggesting the following for vitamin D supplementation: 400-500 IU/day for children aged 12 months and younger, 800-1000 IU/day for 1-10 years of age and 800-2000 IU/day for 11 years and older. In addition, the guidelines committee recommended a serum 25-hydroxyvitamin D concentration at least 30 ng/ml.
The consensus guidelines on bone health in CF suggest that adults with a Z-score of less than -2 by DXA should be offered bisphosphonate therapy [7, 10] ] evaluated seven independent trials of bisphosphonate therapy in CF individuals, of at least 6 months duration. The combined number of participants was 237 adults with CF. The authors concluded that both oral and intravenous bisphosphonates are effective at increasing bone density in CF. They were unable to detect an improvement in fracture rate and recommended larger scale trials to evaluate the efficacy of these medications. They did note that bone pain and flu-like symptoms were common with the intravenous agents.
Additional promising therapies exist, although they have yet to be studied in CF. Teriparatide stimulates osteoblast activity [42] , which is diminished in CF. This could alleviate the decreased anabolic stimulation that is noted. Uncertainties persist over the use of sex steroids in CF individuals. However, other anabolic therapies may still yet play a role in improving bone health in CF. Growth hormone has previously been shown to improve bone accrual in CF [43] . This could be especially effective in CF children with growth restriction. IGF-I therapy has not been tested in CF patients to improve bone health, but this therapy may hold potential. Lastly, denosumab is a promising new drug approved for the treatment of osteoporosis but has yet to be studied in CFBD. Denosumab is an mAb that targets RANKL and therefore acts as an antiresorptive agent for bone disease. Future clinical trials and testing in CF animal models will be needed to test the efficacy of this biologic medication in CFBD.
FUTURE PROJECTIONS
The life expectancy of CF patients is expected to increase. This is especially relevant given the new classes of drugs in development for the CFTR defect itself. One such agent is ivacaftor, which is a CFTR potentiator that targets the G551D CFTR mutation. Although it is useful in a limited number of CF individuals, it paves the way for other future drugs that target CFTR mutations directly. As the impact of CFTR itself on bone metabolism is only beginning to be understood, these new medications may influence bone health directly.
CONCLUSION
CFBD is increasing as the age of the individuals with CF continues to increase. Improved screening methods for adults and children will aid in directing those in need of intervention. In CF, the dynamic state of bone formation and bone resorption is mismatched. A better understanding of the pathogenesis, and the contribution of CFTR, will further improve targets for therapy. Finally, available therapies that currently exist should be studied for this form of bone disease. We will need to not only look at strategies to correct the problem but also develop improved methodologies to prevent occurrence. 
